Business Context and Reporting Period
Quince Therapeutics, Inc. (QNCX) filed a Form 8-K on June 20, 2024, reporting a notice of potential delisting from The Nasdaq Global Select Market. The company is incorporated in Delaware and headquartered in South San Francisco, California.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on regulatory compliance regarding stock listing standards.
Material Changes
The material event reported is the failure to meet Nasdaq Listing Rule 5450(a)(1), which requires a minimum bid price of $1.00 per share. The company's common stock closed below this threshold for 34 consecutive trading days prior to the notice date.
Outlook, Risks, and Management Commentary
- Compliance Period: The company has an initial 180-day compliance period ending December 17, 2024, to regain compliance.
- Requirements: To cure the deficiency, the closing bid price must be at least $1.00 per share for 10 consecutive trading days before the deadline.
- Extension Options: If compliance is not met by December 17, 2024, the company may be eligible for an additional 180-day period if it transfers to The Nasdaq Capital Market and meets specific market value and listing standards.
- Risks: There is no assurance the company will regain compliance or that Nasdaq will grant further extensions. Failure to comply within the allowed periods will result in delisting.
- Management Action: The company intends to monitor the stock price and consider available options to resolve the noncompliance.
Investor Verification Checklist
- Verify the current closing bid price of QNCX common stock relative to the $1.00 threshold.
- Monitor the company's progress toward achieving 10 consecutive trading days above $1.00 before December 17, 2024.
- Check for any future announcements regarding a potential transfer to The Nasdaq Capital Market.
- Review the company's market value of publicly held shares to assess eligibility for the Capital Market extension.